Global molecular imaging market is estimated to be valued at USD 5.32 Bn in 2025 and is expected to reach USD 7.79 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032.
The market for molecular imaging is growing steadily as the incidence of chronic diseases including cancer, neurological disorders, and cardiovascular diseases grows. Advances in imaging technology such as PET and MRI are aiding diagnosis and refining treatment monitoring. Nevertheless, there are challenges in the form of high costs and regulatory issues, which can reduce market growth. Regardless of these challenges, emerging markets such as China and India are seeing a rapid demand for advanced imaging technologies. Chinese firms, for example, are developing PET imaging technology, providing higher resolution and quicker scan times to enhance patient outcomes.
|
Current Events |
Description and its impact |
|
Advancements in Molecular Imaging Technologies |
|
|
Growing Role of Artificial Intelligence (AI) in Molecular Imaging |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Artificial intelligence (AI) plays a transformative role in molecular imaging by enhancing image acquisition, processing, and interpretation. AI algorithms improve image quality, reduce scan times, and enable early and more accurate detection of diseases such as cancer, neurological disorders, and cardiovascular conditions. In nuclear medicine, AI assists in quantifying radiotracer uptake, predicting treatment responses, and personalizing patient care. It also streamlines workflow, supports clinical decision-making, and aids in the development of novel radiopharmaceuticals.
In August 2025, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) introduced the Global Radiopharmaceutical Trial Finder—an innovative, AI-driven platform designed to help researchers, clinicians, and patients quickly identify radiopharmaceutical clinical trials tailored to their specific needs.
Increased inorganic growth initiatives like acquisitions, by major market players, are likely to propel market growth during the forecast period. In August 2024, Siemens Healthineers made a binding offer to buy Novartis's Advanced Accelerator Applications (AAA) business for more than €200 million. The deal fortifies Siemens's market position in the positron emission tomography (PET) radiopharmaceutical market, especially in Europe. The acquisition is scheduled to be completed during the fourth quarter of 2024.
Techniques of molecular imaging are broadly applied for diagnosing and assessing prognosis of cancer; therefore, the growing incidence of cancer across the globe will propel the expansion of the market for global molecular imaging during the forecast period. In 2024, the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) published updated global cancer data. The statistics indicate the following:
Government funding for precision medicine platforms is another key enabler. Quibim raised $50 million in a Series A funding round in January 2025 to take its AI-powered imaging biomarker technology to the next level. The funding is to enhance Quibim's international market presence and step up the growth of precision medicine technologies. The $50 million Series A investment will help Quibim expand its AI-powered imaging biomarker technology, taking precision medicine forward. The funding will also drive international expansion, extending access to innovative healthcare solutions. It speeds up the creation of personalized treatments, enhancing patient care. The increase in resources will further solidify Quibim as a market leader in medical imaging innovation. These trends are leading to a paradigm shift toward closed-loop diagnostic-therapeutic systems, in which imaging directly influences treatment protocols.
By Product Type, Devices Segment is expected to have market dominance in the global molecular imaging market throughout the forecast period and this is on account of the growing demand of molecular imaging devices.
Based on application, the market is divided into cardiovascular, neurology, oncology, respiratory, gastrointestinal, and others applications. Among which, neurology is anticipated to lead the market during the forecast period, and that is due to rising neuro disorders.
On the basis of end user, the market is bifurcated into ambulatory surgical centres, diagnostic imaging centres, and hospitals. Among all these, the hospital segment is anticipated to reign the market throughout the forecast period, and that is due to the immediate care that may bring about appropriate recuperation.
To learn more about this report, Download Free Sample
Among the regions, North America is forecasted to be in leading position in global molecular imaging market during the forecasting period. The North American market is forecasted to account for 33.5 % in 2025. The world molecular imaging market is forecasted to grow sizably in forthcoming years, attributable to rising inorganic growth techniques, including takeover deals by industry leaders.
The United States dominates the market for molecular imaging, fuelled by its sophisticated infrastructure of healthcare facilities, high penetrance of state-of-the-art imaging technologies, and heavy expenditure on research and development. Availability of major market players such as GE Healthcare, Siemens Healthineers, and Philips Healthcare augments its dominant position in the market. The increasing incidence of chronic illnesses, especially cancer, drives demand for molecular imaging methods like PET and MRI, adding to the nation's significant market share.
Germany is among the top nations in Europe for molecular imaging, with its robust healthcare system and highly developed medical technology sector. German companies such as Siemens Healthineers are pioneering the development of advanced molecular imaging equipment. Germany also has a key role in research and development, with various academic and medical centres spearheading innovations in molecular imaging technologies, especially in oncology and neurology.
China is fast becoming a significant player in the molecular imaging industry, driven by its huge population and growing investments in healthcare. The need for sophisticated diagnostic technologies, particularly in oncology and cardiovascular diseases, is on the rise. Chinese firms are also making tremendous contributions to PET and SPECT technology development, enhancing the availability and affordability of molecular imaging in both urban and rural regions. The emphasis on increasing healthcare access by the government also contributes to the growth of the market.
Japan is a leading market for molecular imaging in Asia due to its aging population and high rate of demand for early diagnosis of chronic diseases. Japan is famous for its medical imaging technology innovation, especially in PET and MRI systems. Due to the rising incidence of diseases such as cancer and neurological disorders, Japan will continue to lead the way in molecular imaging with the support of strong government healthcare policies and an established healthcare infrastructure.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 5.32 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.6% | 2032 Value Projection: | USD 7.79 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
GE Healthcare, Bruker Corporation, Fujifilm Holdings Corp., Siemens Healthineers, Koninklijke Philips N.V., Canon Medical Systems Corporation, United Imaging Healthcare Co., Ltd., Mediso Kft., Positron Corporation, Esaote SpA, Carestream Health, Mirada Medical Limited, and Hermes Medical Solutions |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Definition: Molecular imaging is a field of biomedical study that makes it possible to observe, characterize, and quantify biological processes occurring at the cellular and subcellular levels in healthy live beings, including patients. The cellular and molecular illness pathways and mechanisms visible in the context of the living patient are depicted in MI pictures. MI goes beyond the prerequisites and constraints of in vitro or ex vivo biopsy or cell culture laboratory procedures, enabling the study of biologic processes in their own physiologically realistic environment.
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
